Overview

Enzastaurin Versus Lomustine in Glioblastoma

Status:
Completed

Trial end date:
2014-05-01

Target enrollment:

Participant gender:

Summary

This protocol will test the activity of Enzastaurin vs. Lomustine in the treatment of recurrent brain cancer (specifically intracranial glioblastoma multiforme).

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Lomustine